Doximity Appoints New CFO and President, Reports Mixed Q4 FY26 Results
DOCS is trading near its 52-week low of $20.55 (5.0% below the low) on elevated volume (3.6× avg).
Summary
Doximity appointed a new CFO and President with significant equity incentives, while reporting mixed Q4 FY26 financial results and providing guidance for FY27.
Key Events · Executive and Board Changes · DOCS
-
New CFO Appointed
Matthew Sonefeldt, previously Head of Investor Relations at Docusign, was appointed Chief Financial Officer, effective May 13, 2026. He receives an initial equity grant of $12 million in Restricted Stock Units (RSUs), resolving the CFO vacancy following Anna Bryson's resignation on April 17, 2026.
-
New President Appointed
Steven L. Zatz, M.D., a physician executive with extensive digital health experience including WebMD, was appointed President, effective May 13, 2026. He receives an initial equity grant of $2.7 million in RSUs.
-
Q4 FY26 Financial Results
Revenue increased 5% year-over-year to $145.4 million. However, GAAP net income significantly decreased to $19.1 million from $62.5 million in the prior year quarter.
-
FY26 Full Year Financial Results
Total revenues grew 13% year-over-year to $644.9 million. Non-GAAP net income increased to $302.7 million, and Adjusted EBITDA rose 14% to $357.8 million.
Analysis · DOCS · Technology
Doximity announced the appointment of a new Chief Financial Officer and President, resolving the recent CFO vacancy and strengthening its leadership team. The new CFO receives a substantial $12 million RSU grant, indicating a strong commitment to attracting top talent. While the company reported mixed Q4 FY26 financial results with slowing revenue growth and a significant decline in GAAP net income, the full fiscal year showed positive non-GAAP growth and strong cash flow. These leadership changes are crucial for stability and strategic direction, especially as the stock trades near its 52-week low, and could help balance investor concerns regarding the financial performance.
At the time of this filing, DOCS was trading at $19.52 on NYSE in the Technology sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $20.55 to $76.51. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.